DavosPharma
Private Company
Funding information not available
Overview
DavosPharma is a privately held drug development services company founded in 2003, headquartered in Parsippany, New Jersey. It operates as a strategic orchestrator, providing biotech companies with an integrated, fully managed pathway to an Investigational New Drug (IND) application by coordinating CMC, toxicology, regulatory strategy, and vendor management under a single contract. The company leverages a pre-vetted global network of CDMOs and CROs, claiming a track record of over 80 IND filings with a 100% success rate in avoiding clinical holds. Its business model is built on reducing the operational burden and execution risk for emerging biotechs, enabling them to advance assets more efficiently.
Technology Platform
Integrated IND Platform: A service-based operational platform that coordinates a global network of vetted CDMOs and CROs to provide end-to-end, managed drug development services from discovery through IND submission. It integrates CMC, regulatory strategy, toxicology, and QA/QC under single-point accountability.
Opportunities
Risk Factors
Competitive Landscape
DavosPharma competes with large, full-service CDMOs (e.g., Lonza, Catalent) and CROs (e.g., IQVIA, Labcorp) that offer strategic consulting, as well as niche regulatory consulting firms and other drug development orchestrators. Its differentiation is its vendor-agnostic network, claimed 100% IND success rate, and single-contract, fully managed service model.